Literature DB >> 24159162

HIV, EBV, and monoclonal gammopathy.

Sham Mailankody1, Ola Landgren.   

Abstract

In this issue of Blood, Ouedraogo et al have investigated the role of HIV and Epstein-Barr virus (EBV) replication in the persistence of monoclonal gammopathy.1 It has been known for some time that patients with HIV infection have an increased incidence of monoclonal gammopathy and plasma cell dyscrasias.2,3 The exact mechanism of monoclonal gammopathy in patients with HIV infection is unknown, but in many patients the monoclonal gammopathy and other B-cell abnormalities can be reversed with antiretroviral therapy. However, a proportion of patients will have persistent monoclonal gammopathy.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24159162      PMCID： PMC3811169          DOI： 10.1182/blood-2013-08-522508

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  10 in total

1.  Monoclonal and oligoclonal gammopathies in liver transplant recipients.

Authors:  H Pham; A Lemoine; O Sol; D Azoulay; P Royer; D Samuel; C Charpentier; H Bismuth; B Debuire
Journal:  Transplantation       Date:  1994-07-27       Impact factor: 4.939

2.  Prospective evaluation of epstein-barr virus reactivation after stem cell transplantation: association with monoclonal gammopathy.

Authors:  Patrizia Chiusolo; Elisabetta Metafuni; Paola Cattani; Nicola Piccirillo; Rosaria Santangelo; Stefania Manzara; Silvia Bellesi; Teresa De Michele; Giuseppe Leone; Simona Sica
Journal:  J Clin Immunol       Date:  2010-08-25       Impact factor: 8.317

3.  HIV-associated monoclonal gammopathy: a retrospective analysis of 25 patients.

Authors:  Sashi Amara; Bruce J Dezube; Timothy P Cooley; Liron Pantanowitz; David M Aboulafia
Journal:  Clin Infect Dis       Date:  2006-10-02       Impact factor: 9.079

4.  A long-term study of prognosis in monoclonal gammopathy of undetermined significance.

Authors:  Robert A Kyle; Terry M Therneau; S Vincent Rajkumar; Janice R Offord; Dirk R Larson; Matthew F Plevak; L Joseph Melton
Journal:  N Engl J Med       Date:  2002-02-21       Impact factor: 91.245

5.  Monoclonal gammopathy of undetermined significance (MGUS) is associated with an increased frequency of Epstein-Barr Virus (EBV) latently infected B lymphocytes in long-term renal transplant patients.

Authors:  N Babel; F Schwarzmann; A Pruss; H-D Volk; P Reinke
Journal:  Transplant Proc       Date:  2004-11       Impact factor: 1.066

6.  Monoclonal and oligoclonal gammopathies in heart-transplant recipients.

Authors:  I Myara; G Quenum; M Storogenko; D Tenenhaus; R Guillemain; N Moatti
Journal:  Clin Chem       Date:  1991-08       Impact factor: 8.327

Review 7.  Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis.

Authors:  Andrew E Grulich; Marina T van Leeuwen; Michael O Falster; Claire M Vajdic
Journal:  Lancet       Date:  2007-07-07       Impact factor: 79.321

8.  Circulating serum free light chains as predictive markers of AIDS-related lymphoma.

Authors:  Ola Landgren; James J Goedert; Charles S Rabkin; Wyndham H Wilson; Kieron Dunleavy; Robert A Kyle; Jerry A Katzmann; S Vincent Rajkumar; Eric A Engels
Journal:  J Clin Oncol       Date:  2010-01-04       Impact factor: 44.544

9.  Pivotal role of HIV and EBV replication in the long-term persistence of monoclonal gammopathy in patients on antiretroviral therapy.

Authors:  David Eric Ouedraogo; Alain Makinson; Jean-Pierre Vendrell; Marie-Laure Casanova; Nicolas Nagot; Renaud Cezar; Karine Bollore; Yassine Al Taaba; Vincent Foulongne; Stéphanie Badiou; Johannes Viljoen; Jacques Reynes; Philippe Van de Perre; Edouard Tuaillon
Journal:  Blood       Date:  2013-08-12       Impact factor: 22.113

10.  Plasma cell neoplasms in US solid organ transplant recipients.

Authors:  Eric A Engels; Christina A Clarke; Ruth M Pfeiffer; Charles F Lynch; Dennis D Weisenburger; Todd M Gibson; Ola Landgren; Lindsay M Morton
Journal:  Am J Transplant       Date:  2013-05-01       Impact factor: 9.369
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.